RP2
DEAD

Serial Number

97789361

Owner

Replimune Limited

Attorney

Melanie Howard

Filing Date

Feb 10, 2023

Add to watchlist:

No watchlists yet
View on USPTO

RP2 Trademark

Serial Number: 97789361

RP2 is a trademark filed by Replimune Limited on February 10, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Replimune Limited (14 trademarks)

69 Innovation Dr., Milton Park, Abingdon
Oxfordshire OX144RQ , GB

Entity Type: 99

Trademark Details

Filing Date

February 10, 2023

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations; viruses; viruses for the treatment of disease; viruses for the treatment of cancer; viruses for inducing immune response; pharmaceuticals; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response; vaccines; immunotherapy products; gene therapy products; Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders

Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid

Filing History

ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Oct 18, 2023 MAB1
ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
Oct 18, 2023 MAB1
ABANDONMENT - EXPRESS MAILED
Oct 18, 2023 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Oct 17, 2023 EXAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 1, 2023 NWOS
NEW APPLICATION ENTERED
Feb 14, 2023 NWAP